BioNexus Gene Company Insiders

BioNexus Gene Management Team Effectiveness

The company has return on total asset (ROA) of (0.1405) % which means that it has lost $0.1405 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2475) %, meaning that it created substantial loss on money invested by shareholders. BioNexus Gene's management efficiency ratios could be used to measure how well BioNexus Gene manages its routine affairs as well as how well it operates its assets and liabilities. As of July 20, 2025, Return On Tangible Assets is expected to decline to -0.16. In addition to that, Return On Capital Employed is expected to decline to -0.19. At present, BioNexus Gene's Debt To Assets are projected to slightly decrease based on the last few years of reporting. The current year's Common Stock Shares Outstanding is expected to grow to about 2.8 M. The current year's Net Income Applicable To Common Shares is expected to grow to about 907.5 K

BioNexus Gene Workforce Comparison

BioNexus Gene Profit Margins

The company has Profit Margin (PM) of (0.23) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.27) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.27.

BioNexus Gene Insider Trading

BioNexus Gene Notable Stakeholders

The success or failure of an entity such as BioNexus Gene Lab often depends on how effective the management is. BioNexus Gene management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioNexus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioNexus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of BioNexus Gene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioNexus Gene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BioNexus Gene's management manipulating its earnings.

When running BioNexus Gene's price analysis, check to measure BioNexus Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNexus Gene is operating at the current time. Most of BioNexus Gene's value examination focuses on studying past and present price action to predict the probability of BioNexus Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNexus Gene's price. Additionally, you may evaluate how the addition of BioNexus Gene to your portfolios can decrease your overall portfolio volatility.